|
|
|
Trastuzumab deruxtecan (7)
|
Enhertu®
|
Daiichi Sankyo Deutschland GmbH
|
Oncological diseases
|
HER2-positive adenocarcinoma of the stomach or the gastro-oesophageal junction, following trastuzumab-based therapy
|
360–600
|
100%
Indication of
minor additional benefit
|
|
|
|
Trastuzumab deruxtecan (6)
|
Enhertu®
|
Daiichi Sankyo Deutschland GmbH
|
Oncological diseases
|
Breast cancer, HR+, HER2-low or -ultralow, following at least one course of endocrine therapy
|
1,615–6,200
|
100%
Hint for
minor additional benefit
|
|
|
|
Trastuzumab deruxtecan (5)
|
Enhertu®
|
Daiichi Sankyo Deutschland GmbH
|
Oncological diseases
|
Non-small cell lung cancer, HER2(ERBB2) mutation, pre-treated
|
75–219
|
100%
additional benefit not proven
|
|
|
|
Trastuzumab deruxtecan (3)
|
Enhertu®
|
Daiichi Sankyo Deutschland GmbH
|
Oncological diseases
|
Adenocarcinoma (AC) of the stomach or gastro-oesophageal junction, HER2-positive, after trastuzumab-based therapy
|
110–170
470–770
|
100%
additional benefit not proven
repealed subpopulations
|
|
|
|
Trastuzumab deruxtecan (4)
|
Enhertu®
|
Daiichi Sankyo Deutschland GmbH
|
Oncological diseases
|
Breast carcinoma (BC), HER2-low, pre-treated
|
1,350–4,700
|
100%
Indication of
considerable additional benefit
|
|
|
|
Trastuzumab deruxtecan (1)
|
Enhertu®
|
Daiichi Sankyo Deutschland GmbH
|
Oncological diseases
|
Breast carcinoma (BC), HER2+, after 1 prior therapy
|
3,370–3,750
|
100%
Indication of
non-quantifiable additional benefit
|
|
|
|
Trastuzumab deruxtecan (2)
|
Enhertu®
|
Daiichi Sankyo Deutschland GmbH
|
Oncological diseases
|
Breast carcinoma (BC), HER2+, at least 2 previous therapies
|
1,350–1,640
|
100%
Indication of
considerable additional benefit
|
|
|
start postponed
|
Trastuzumab deruxtecan (8)
|
Enhertu®
|
Daiichi Sankyo Deutschland GmbH
|
Oncological diseases
|
Solid tumours, HER2+ (IHC3+), previously treated
|
n.d.
|
active procedure
|
